-

USAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic Accounts

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Steven Lutz to vice president of strategic accounts. In this role, Lutz oversees the organization’s commercial strategy to drive continued growth and market share in alignment with the company’s business objectives.

An accomplished sales and marketing executive, Lutz has more than three decades of experience leading multi-faceted business development strategies in the pharmaceutical and biotechnology sectors.

At USAntibiotics, Lutz leads the overarching sales strategy with a focus on initiatives to optimize commercial efficiency, strengthen customer relationships and oversee third-party logistics.

“Steven’s proven success in driving strategic growth in the pharmaceutical market makes him a great addition to our team,” said Patrick Cashman, president, USAntibiotics. “His leadership will be instrumental as we further expand our market presence and advance our mission of producing life-saving antibiotics for the benefit of all Americans. We are delighted to welcome Steven to USAntibiotics and our executive leadership team.”

Before joining USAntibiotics, Lutz was on the leadership team at Neos Therapeutics. Prior to that, he co-founded Cornerstone Therapeutics, now Chiesi USA.

About USAntibiotics

USAntibiotics is the only U.S. manufacturer of Amoxicillin and Amoxicillin Clavulanate, commonly known as Amoxil® and Augmentin®. Based in Bristol, Tennessee, it operates a world-class, 394,000 square foot antibiotics production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare® family of companies. For more information, visit www.us-antibiotics.com.

Contacts

media@us-antibiotics.com

Industry:

USAntibiotics

Release Versions
English

Contacts

media@us-antibiotics.com

More News From USAntibiotics

USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs. In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packagi...

As Amoxicillin Shortage Continues, USAntibiotics Urges Lawmakers to Consider Policies and Partnerships That Support U.S. Drug Manufacturers

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxicillin Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, released the following statement ahead of the U.S. House Energy and Commerce Committee Subcommittee on Oversight and Investigations hearing titled “Examining The Root Causes Of Drug Shortages: Challenges In Pharmaceutical Drug Supply Chains.” “Today’s hearing is an opportunity to ide...
Back to Newsroom